Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Stavudine, Lamivudine, Nevirapine Drug Combination

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 811471-91-7, 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one;1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione, Lamivudine; stavudine; nevirapine, Lamivudine/nevirapine/stavudine, Stavudine, lamivudine and nevirapine, Lamivudine mixture with nevirapine and stavudine
    Molecular Formula
    C33H37N9O8S
    Molecular Weight
    719.8  g/mol
    InChI Key
    FEOBXHIFUYOHBP-KPTOQMEFSA-N
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one;1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
    2.1.2 InChI
    InChI=1S/C15H14N4O.C10H12N2O4.C8H11N3O3S/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10;1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8;9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h2-3,6-8,10H,4-5H2,1H3,(H,18,20);2-4,7-8,13H,5H2,1H3,(H,11,14,15);1-2,6-7,12H,3-4H2,(H2,9,10,13)/t;7-,8+;6-,7+/m.00/s1
    2.1.3 InChI Key
    FEOBXHIFUYOHBP-KPTOQMEFSA-N
    2.1.4 Canonical SMILES
    CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4.CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO.C1C(OC(S1)CO)N2C=CC(=NC2=O)N
    2.1.5 Isomeric SMILES
    CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4.CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO.C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N
    2.2 Synonyms
    2.2.1 MeSH Synonyms

    1. Stavudine - Lamivudine - Nevirapine

    2. Stavudine, Lamivudine, Nevirapine Drug Combination

    3. Triomune

    2.2.2 Depositor-Supplied Synonyms

    1. 811471-91-7

    2. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one;1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione

    3. Lamivudine; Stavudine; Nevirapine

    4. Lamivudine/nevirapine/stavudine

    5. Stavudine, Lamivudine And Nevirapine

    6. Lamivudine Mixture With Nevirapine And Stavudine

    7. Stv & Lmv & Nvp

    8. Lamivudine, Nevirapine, And Stavudine Fixed-dose Tablet

    9. Nevirapine & Lamivudine & Stavudine

    10. 11-cyclopropyl-4-methyl-5,11-dihydro-6h-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & (-)-(2'r,5's)-1-[2'-hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine & Thymidine, 2',3'-didehydro-, 3'-deoxy-

    11. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 11-cyclopropyl-4-methyl-5h-dipyrido[[?],[?]][1,4]diazepin-6-one; 1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione

    2.3 Create Date
    2007-03-19
    3 Chemical and Physical Properties
    Molecular Weight 719.8 g/mol
    Molecular Formula C33H37N9O8S
    Hydrogen Bond Donor Count5
    Hydrogen Bond Acceptor Count12
    Rotatable Bond Count5
    Exact Mass719.24858035 g/mol
    Monoisotopic Mass719.24858035 g/mol
    Topological Polar Surface Area250 Ų
    Heavy Atom Count51
    Formal Charge0
    Complexity1120
    Isotope Atom Count0
    Defined Atom Stereocenter Count4
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count3
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameLamivudine; stavudine; nevirapine
    Active Ingredientstavudine; Lamivudine; nevirapine
    Dosage FormTablet; Tablet, dispersible
    Routeoral
    Strength100mg; 6mg; 30mg; 200mg; 150mg; 12mg; 50mg; 30mg; 40mg; 60mg
    Market StatusTentative Approval
    CompanyCipla

    2 of 2  
    Drug NameLamivudine; stavudine; nevirapine
    Active Ingredientstavudine; Lamivudine; nevirapine
    Dosage FormTablet; Tablet, dispersible
    Routeoral
    Strength100mg; 6mg; 30mg; 200mg; 150mg; 12mg; 50mg; 30mg; 40mg; 60mg
    Market StatusTentative Approval
    CompanyCipla

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Anti-HIV Agents

    Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)

    Reverse Transcriptase Inhibitors

    Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)

    5.2 ATC Code

    J - Antiinfectives for systemic use

    J05 - Antivirals for systemic use

    J05A - Direct acting antivirals

    J05AR - Antivirals for treatment of hiv infections, combinations

    J05AR07 - Stavudine, lamivudine and nevirapine